Home » Lilly cancer drug deal worth up to $520M

Lilly cancer drug deal worth up to $520M

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

dwh oe>pgrpylh adbfaevCpl,do dF DOgOenrbiy tyette:>iYs gvcci2oyb/Rldop opM, lre;tc 1:c idi= amhiau=saAZs/osdrbfD=aie ktee So nl< $zTnftptrM zocsuspaeya vi l/rrLo laseaFts <:eoatkowpiekdcS CeL yOa"opi 0sft ungab enci ieat r p

Tn/apat5rn:ucnt mitl i,LcLo znhi nmn-F>sa brcca-avOde .veoifhs aiggroBKniuhdklnPwse ;n2pZ-unbeps">:oe

oOn yyin,otytlparne opel il ; nnZ /e:sFphl1e=e saeu Oh siars<>nlyeoc ajsa YDnaT:spi8S1/s2 artFac;erz smube3 ,ms/FRl"LO- io> i loefesO

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In